Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Debt (2020 - 2023)

Kiora Pharmaceuticals' Total Debt history spans 5 years, with the latest figure at $495000.0 for Q3 2023.

  • For Q3 2023, Total Debt rose 57.79% year-over-year to $495000.0; the TTM value through Sep 2023 reached $495000.0, up 57.79%, while the annual FY2020 figure was $278190.0, N/A changed from the prior year.
  • Total Debt reached $495000.0 in Q3 2023 per KPRX's latest filing, up from $313853.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $495000.0 in Q3 2023 to a low of $278190.0 in Q2 2020.
  • Average Total Debt over 4 years is $314438.1, with a median of $297877.5 recorded in 2022.
  • The largest YoY upside for Total Debt was 57.79% in 2023 against a maximum downside of 3.99% in 2023.
  • A 4-year view of Total Debt shows it stood at $278190.0 in 2020, then changed by 0.0% to $278190.0 in 2021, then grew by 12.77% to $313714.0 in 2022, then surged by 57.79% to $495000.0 in 2023.
  • Per Business Quant, the three most recent readings for KPRX's Total Debt are $495000.0 (Q3 2023), $313853.0 (Q2 2023), and $313299.0 (Q1 2023).